Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number, morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related complex (ARC) patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco

Criteria

Inclusion Criteria

Patients must have the following:

• Stage III or IV HIV infection.

• Provide informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

• Kaposi's sarcoma lesions in the proposed treatment sites.

• Liable to require radiation or chemotherapy during the course of the study.

• Not likely to survive the length of the study.

• Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.:

• holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine.

Concurrent Medication:

Excluded:

• Other Immunomodulators.

Concurrent Treatment:

Excluded:

• Radiation.

Patients with the following are excluded:

• Kaposi's sarcoma lesions in the proposed treatment sites.

• Liable to require radiation or chemotherapy during the course of the study.

• Not likely to survive the length of the study.

• Obvious ultra-violet-irradiated skin damage in the treatment areas.

• Allergy to lidocaine.

Prior Medication:

Excluded:

• Prior DNCB therapy.